image credit- shutterstock
Alamar Biosciences, a US-based company powering precision proteomics to enable the earliest detection of disease, has announced the signing of five new distribution partners to expand its global presence.
The company has partnered with established industry leaders across key international markets to enhance access to its innovative proteomics technologies.
The newly signed distribution partners include GeneWorks – Australia and New Zealand; Genomax – Singapore; PhileKorea – South Korea; Scrum Inc. – Japan; and Spinco – India
Alamar’s technology empowers scientists to achieve groundbreaking insights in biomarker discovery, drug development, and disease research. Through these new partnerships, researchers in Asia-Pacific (APAC) will now have enhanced access to Alamar’s cutting-edge platforms and technical support.
The company’s proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today.
